Skip to content

NKT cell therapy for malignant tumors

A study for the safety of NKT cell therapy using alpha-galactosylceramide-pulesed dendritic cells for malignant tumors - NKT cell therapy using alphaGC-DCs for malignant tumors

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030220374
Enrollment
3
Registered
2022-10-11
Start date
2022-10-14
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

blood collection for cell culture and tests. Administration of therapeutic cells 4 times.

Sponsors

Takimoto Rishu
Lead Sponsor
MEDINET Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Be diagnosed with malignant tumor by imaging findings or pathological or cytological study. (2) Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1. (3) Be at age 18 or older. (4) Visit outpatient department on schedule. (5) Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed. (6) Provide agreement of the attending doctor to participate in this study. (7) Provide written consent to participate this study.

Exclusion criteria

Exclusion criteria: (1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. (2)Have a history of a serious drug allergy. (3)Have a positive result of HIV antibody. (4)Have a serious cardiac disorder. (5)Have an active autoimmune disorder. (6)Have a concurrent cancer. (7)Have an infectious disorder that is difficult to control. (8)Be a female who is pregnant, lactating, or with a possibility of pregnancy. (9)A patient who is judged as inadequate for enrolment by doctors is excluded

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Efficacy, Immunological response

Countries

Japan

Contacts

Public ContactEri Oguma

Koshikai, Non-profit Medical Corporation

citeg@j-immunother.com+81-3-5244-5751

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026